0001415889-15-000615.txt : 20150219 0001415889-15-000615.hdr.sgml : 20150219 20150219180008 ACCESSION NUMBER: 0001415889-15-000615 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150217 FILED AS OF DATE: 20150219 DATE AS OF CHANGE: 20150219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11085 TORREYANA ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 11085 TORREYANA ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rasmussen Torsten CENTRAL INDEX KEY: 0001291881 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 15632970 MAIL ADDRESS: STREET 1: SMEDENS AGER 6 STREET 2: NORUP CITY: DK-7182 BREDSTEN STATE: G7 ZIP: DK-7182 4 1 form4-02192015_030200.xml X0306 4 2015-02-17 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001291881 Rasmussen Torsten 11085 TORREYANA ROAD #100 SAN DIEGO CA 92121 true false false false Common Stock 2015-02-17 4 M 0 2780 8.49 A 11280 I See footnote Common Stock 2015-02-17 4 M 0 7067 8.49 A 18347 I See footnote Common Stock 2015-02-17 4 M 0 10000 1.36 A 28347 I See footnote Common Stock 2015-02-17 4 S 0 19847 35.0453 D 8500 I See footnote Stock option (right to buy) 8.49 2015-02-17 4 M 0 2780 0 D 2018-06-12 Common Stock 2780 0 I See footnote Stock option (right to buy) 8.49 2015-02-17 4 M 0 7067 0 D 2018-06-12 Common Stock 7067 0 I See footnote Stock option (right to buy) 1.36 2015-02-17 4 M 0 10000 0 D 2022-06-07 Common Stock 10000 0 I See footnote Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.10 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 8, 2012. /s/ Glenn F. Baity, Attorney-in-Fact 2015-02-19